JP Morgan Chase’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

JP Morgan Chase’s Portfolio SCPS Stock Details SCPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,000	Closed	-$1K	–	7298
2022 Q3	$1K	Hold	5,000	–	–	﹤0.01%	6409
2022 Q2	$2K	Hold	5,000	–	–	﹤0.01%	6327
2022 Q1	$3K	Hold	5,000	–	–	﹤0.01%	6402
2021 Q4	$8K	Hold	5,000	–	–	﹤0.01%	6373
2021 Q3	$21K	Sell	5,000 -4,338	-46%	-$22.3K	﹤0.01%	6040
2021 Q2	$67K	Sell	9,338 -11,189	-55%	-$79.6K	﹤0.01%	5661
2021 Q1	$173K	Buy	+20,527	New	+$215K	﹤0.01%	5205

Other funds holding SCPS

MRCM

M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return

JP Morgan Chase's SCPS Position: Q4 2022 in Review

JP Morgan Chase sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q4 2022, closing a stake of 5,000 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in SCPS in Q1 2021 and held it in 7 quarters. The position peaked at $173K in Q1 2021. 1 fund tracked by Wall St. Rank holds SCPS as of Q4 2022.

JP Morgan Chase reported no remaining Scopus BioPharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
JP Morgan Chase sold 5,000 Scopus BioPharma Inc. Common Stock shares in Q4 2022, an estimated $1K.
JP Morgan Chase first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 7 quarters.
JP Morgan Chase's Scopus BioPharma Inc. Common Stock position peaked at $173K in Q1 2021.
1 fund tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.